TGFB1 and systemic sclerosis: Its application in vitro and standardized SSc mouse models demonstrated good biocompatibility, prolonged drug release, and CXCL4/TGF-β dual-targeted immunomodulation, along with anti-inflammatory, pro-angiogenic, and antifibrotic effects.